Companies
- Companies
- Company details
Acologix Inc
Out-licensing
A Human Derived Small Peptide for the Treatment of Osteoporosis: Phase II Clinical Development of AC-100 More
Phase III Clinical Development of TRK-820 (AC-820) for the Treatment of Uremic Pruritus More
Treatment of Hyperphosphataemia Associated with Chronic Kidney Disease: Development of Phosphatonin, an Endogenous Polypeptide Hormone More
Related Reports
Market Research Reports provided by reports.iptechex.com
Dec 2010 - 36 pages - $500
Nov 2010 - 70 pages - $600
Mar 2011 - 25 pages - $250
Jul 2010 - 37 pages - $750
Feb 2011 - 44 pages - $500
Dec 2010 - 48 pages - $1,000
Dec 2010 - 35 pages - $500
May 2011 - 36 pages - $500
Apr 2011 - 47 pages - $500
Aug 2011 - 48 pages - $500
Contact details
Yoshinari Kumagai
Head office
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us